AI assistant
Sending…
AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2017
Dec 5, 2017
31580_dirs_2017-12-05_3e10c0e4-4c31-4a9c-b526-cdd626693673.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2017-12-03
Reporting Person: FOUSE JACQUALYN A (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-12-03 | Stock option (right to buy) | $61.17 | A | 16000 | Acquired | 2027-12-02 | Common stock (16000) | Direct |
Footnotes
F1: This option was granted on December 3, 2017. The shares underlying this option vest as to 25% of the underlying shares on December 2, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter.
More from AGIOS PHARMACEUTICALS, INC.
Interim / Quarterly Report
2026
Apr 29
Earnings Release
2026
Apr 29
Annual Report
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Major Shareholding Notification
2026
Mar 26
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3